TAS3681, a new type of androgen receptor antagonist, disrupts aberrant AR signaling that drives tumor resistance to AR-targeted therapies by downregulating full-length and splice variant AR

被引：0
|
作者：
Kajiwara, D. [1 ]
Minamiguchi, K. [1 ]
Seki, M. [1 ]
Mizutani, H. [1 ]
Yamamura, K. [1 ]
Okajima, S. [1 ]
Sasaki, E. [1 ]
Utsugi, T. [1 ]
Iwasawa, Y. [1 ]
机构：
[1] Taiho Pharmaceut Co Ltd, Discovery & Preclin Res Div, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32977-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
385
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 10 条
  • [1] The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR.
    Kajiwara, Daisuke
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Mizutani, Hiroya
    Yamamura, Keisuke
    Okajima, Shigeo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [2] TAS3681, a novel type of AR antagonist with AR downregulating activity, as a new targeted therapy for aberrant AR-driven prostate cancer.
    Seki, Masanao
    Minamiguchi, Kazuhisa
    Kajiwara, Daisuke
    Mizutani, Hiroya
    Yoshida, Shohei
    Sasaki, Eiji
    Utsugi, Teruhiro
    Iwasawa, Yoshikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [3] Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy
    Saito, Shun.
    Fujimaki, Takahiro
    Panbangred, Watanalai
    Igarashi, Yasuhiro
    Imoto, Masaya
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (08) : 2728 - 2732
  • [4] Effect of a new type androgen receptor antagonist, TAS3681, on ligand-independent AR activation through its AR downregulation activity.
    Kajiwara, Daisuke
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Mizutani, Hiroya
    Aoyagi, Hiroki
    Okajima, Shigeo
    Sasaki, Eiji
    Utsugi, Teruhiro
    Iwasawa, Yoshikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [5] Androgen receptor splice variant 7 (AR-V7) and AR full-length (AR-FL) as predictive biomarkers of therapeutic resistance: partners in crime?
    Barbier, Roberto H.
    Chau, Cindy H.
    Figg, William D.
    BJU INTERNATIONAL, 2019, 124 (04) : 549 - 550
  • [6] First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
    De Bono, Johann S.
    Cook, Natalie
    Yu, Evan Y.
    Lara, Primo
    Wang, Judy S.
    Yamasaki, Yoshihiko
    Yamamiya, Ikuo
    Gao, Ping
    Calleja, Elizabeth Martine
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer
    Del Re, Marzia
    Crucitta, Stefania
    Sbrana, Andrea
    Rofi, Eleonora
    Paolieri, Federico
    Gianfilippo, Giulia
    Galli, Luca
    Falcone, Alfredo
    Morganti, Riccardo
    Porta, Camillo
    Efstathiou, Eleni
    van Schaik, Ron
    Jenster, Guido
    Danesi, Romano
    BJU INTERNATIONAL, 2019, 124 (04) : 693 - 700
  • [8] Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer
    Zhang, Tian
    Karsh, Lawrence I.
    Nissenblatt, Michael J.
    Canfield, Steven E.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (01) : 1 - 10
  • [9] Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
    Cattrini, Carlo
    Rubagotti, Alessandra
    Zinoli, Linda
    Cerbone, Luigi
    Zanardi, Elisa
    Capaia, Matteo
    Barboro, Paola
    Boccardo, Francesco
    CANCERS, 2019, 11 (09)
  • [10] Dynamic pro-survival signaling mediates resistance to androgen receptor targeted therapy in AR-v7 splice variant expressing prostate cancer models
    Pilling, Amanda
    Hwang, Clara
    CANCER RESEARCH, 2018, 78 (13)
1